Subscribe To
ARDX / 3 Cheap Biotech Stocks That Smart Investors Will Snap Up Now
ARDX News
By The Motley Fool
October 31, 2023
Why Ardelyx Stock Soared Today
Ardelyx delivered a surprise profit thanks to strong sales of Ibsrela, its first FDA-approved product. The company has also commenced the launch of Xp more_horizontal
By Seeking Alpha
October 31, 2023
Ardelyx, Inc. (ARDX) Q3 2023 Earnings Call Transcript
Ardelyx, Inc. (NASDAQ:ARDX ) Q3 2023 Earnings Conference Call October 31, 2023 8:00 AM ET Company Participants Caitlin Lowie - Vice President of Corpo more_horizontal
By InvestorPlace
October 29, 2023
3 Penny Stocks to Buy and Hold for the Next 10 Years
Despite 18 months of rising interest rates from the Fed, the U.S. economy held a steady 4.9% growth rate in Q3, defying the gloomier economic predicti more_horizontal
By Zacks Investment Research
October 19, 2023
Ardelyx (ARDX) Up on FDA Nod to Xphozah for Hyperphosphatemia
Ardelyx (ARDX) gets FDA approval for Xphozah to reduce serum phosphorus in adult patients with kidney disease on dialysis as an add-on therapy. The st more_horizontal
By The Motley Fool
October 18, 2023
Why Ardelyx Stock Popped Today
Late yesterday, Ardelyx announced that the FDA has approved its first-in-class chronic kidney disease drug Xphozah. The drug adds an important new tre more_horizontal
By GlobeNewsWire
October 18, 2023
Ardelyx to Report Third Quarter 2023 Financial Results on October 31, 2023
WALTHAM, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develo more_horizontal
By PennyStocks
October 18, 2023
4 Top Penny Stocks To Buy For Under $5
Looking at the stock market today is like watching an action movie. One minute the bulls are stampeding and stocks are rising. more_horizontal
By InvestorPlace
October 18, 2023
FDA Sends ARDX Stock Soaring After Approving Ardelyx's Kidney Disease Drug
Ardelyx (NASDAQ: ARDX ) stock is climbing today after the U.S. Food and Drug Administration (FDA) approved the firm's treatment for excessive phosphat more_horizontal